bone biologics
-
Financial
Bone Biologics Announces Closing of $2.0 Million Public Offering
BURLINGTON, Mass., March 6, 2024–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic…
Read More » -
Financial
Bone Biologics Announces Pricing of $2.0 Million Public Offering
BURLINGTON, Mass., March 4, 2024–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic…
Read More » -
Biologics
Bone Biologics Reports Progress With NB1 Clinical Program
BURLINGTON, Mass., March 1, 2024–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress…
Read More » -
Biologics
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Brings 20+ years of experience in finance and business operations at both public and private life sciences companies BURLINGTON, Mass.,…
Read More » -
Financial
Bone Biologics Announces 1-for-8 Reverse Stock Split
BURLINGTON, Mass., December 18, 2023 –(BUSINESS WIRE)– Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of…
Read More » -
Financial
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BURLINGTON, Mass., November 20, 2023–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today…
Read More » -
Financial
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BURLINGTON, Mass., November 17, 2023–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today…
Read More » -
Financial
Bone Biologics Prices $5.0 Million Underwritten Public Offering
BURLINGTON, Mass., June 15, 2023–(BUSINESS WIRE)– Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products…
Read More » -
Biologics
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Company plans to begin 30-patient trial later this year April 11, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a…
Read More » -
Spine
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
January 26, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces…
Read More » -
Biologics
Bone Biologics CEO Issues Letter to Stockholders
BURLINGTON, Mass., October 25, 2022 (BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today…
Read More » -
Spine
Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
Secures rhNELL-1 Carrier for Bone Regeneration Spine Fusion Product March 7, 2022 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer…
Read More » -
Biologics
Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
October 13, 2021 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for…
Read More » -
Biologics
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
January 7, 2020 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis…
Read More » -
Financial
Bone Biologics Completes $5.9 Million of Financing
July 23, 2018 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets,…
Read More »